

ASX Release

SUDA TOP-20 SHAREHOLDERS

PERTH, AUSTRALIA – 8 June 2015: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, provides an updated top-20 shareholder list following the capital raising in March 2015.

Company: SUDA LIMITED
ACN: 090 987 250
Top Listing - Grouped



1	GROUP # 647070	77,440,997	6.82
.	CITICORP NOMINEES PTY LIMITED	77,440,997	6.82
2	GROUP # 889383	67,048,409	5.9
.	J P MORGAN NOMINEES AUSTRALIA LIMITED	67,048,409	5.9
3	BRISQOT NOMINEES PTY LTD <HOUSE HEAD NOMINEE NO 1 A/C>	52,203,351	4.6
4	GROUP # 889326	38,416,192	3.38
.	UBS NOMINEES PTY LTD <TP00014 15 A/C>	1,200,000	0.11
.	UBS NOMINEES PTY LTD	37,216,192	3.28
5	GROUP # 630102	28,431,821	2.5
.	NATIONAL NOMINEES LIMITED	28,431,821	2.5
6	GROUP # 889118	21,422,478	1.89
.	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	9,823,999	0.86
.	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED - A/C 3	11,598,479	1.02
7	CS FOURTH NOMINEES PTY LTD	16,808,803	1.48
8	BAMBER INVESTMENTS PTY LTD	15,050,000	1.32
9	KAMALA HOLDINGS PTY LTD <KAMALA 1994 SUPER FUND A/C>	13,483,334	1.19
10	ONICAS INVESTMENTS PTY LTD	11,089,187	0.98
11	MR THOMAS PAUL MCGELLIN + MS TANYA MARGARET KARAL <SKI SUPERANNUATION FUND A/C>	9,354,665	0.82
12	MS GIOVANNA LINA GAN	9,300,000	0.82
13	ZERRIN INVESTMENTS PTY LTD	8,331,666	0.73
14	PETO PTY LTD <1953 SUPER FUND A/C>	7,440,000	0.65
15	M & S BROOKE PTY LTD	7,176,000	0.63
16	DR MICHAEL WUNSH <SUPER PLAN A/C>	7,000,000	0.62
17	SOMERSET CORPORATION PTY LTD	6,861,462	0.6
18	GROUP # 591258	6,816,999	0.6
.	BNP PARIBAS NOMS PTY LTD <DRP>	6,816,999	0.6
19	BAMBER INVESTMENTS PTY LTD	6,000,000	0.53
20	SEMPAI INVESTMENTS PTY LTD	5,900,000	0.52

Totals: Top 20 holders of SUD ORDINARY FULLY PAID
Total Remaining Holders Balance
Total Holders Balance

415,575,364
720,435,223
1,136,010,587

36.58
63.42
100

Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA LTD
 Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au